These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 6418264)

  • 21. Results of a Dutch trial with the LHRH agonist buserelin in patients with metastatic prostatic cancer and results of EORTC studies in prostatic cancer.
    Debruyne FM
    Am J Clin Oncol; 1988; 11 Suppl 1():S33-5. PubMed ID: 2968760
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sustained suppression of testosterone production by the luteinising-hormone releasing-hormone agonist buserelin in patients with advanced prostate carcinoma. A new therapeutic approach?
    Borgmann V; Hardt W; Schmidt-Gollwitzer M; Adenauer H; Nagel R
    Lancet; 1982 May; 1(8281):1097-9. PubMed ID: 6122893
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [1st clinical results of the treatment of locally advanced prostatic cancer with a powerful LH-RH analog: buserelin acetate].
    Nagel R; Borgmann V; Al-Abadi H; Schmidt-Gollwitzer M
    J Urol (Paris); 1983; 89(9):669-76. PubMed ID: 6425419
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A prospective randomized single-blind comparative trial of nafarelin acetate with buserelin in long-protocol gonadotrophin-releasing hormone analogue controlled in-vitro fertilization cycles.
    Lockwood GM; Pinkerton SM; Barlow DH
    Hum Reprod; 1995 Feb; 10(2):293-8. PubMed ID: 7769051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Three-monthly GnRH agonist (buserelin) for prostatic cancer.
    Waxman J; Sandow J; Abel P; Barton C; Keane P; Williams G
    Br J Urol; 1990 Jan; 65(1):43-5. PubMed ID: 2107012
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Treatment of patients with advanced cancer of the prostate using a slow-release (depot) formulation of the LHRH agonist ICI 118630 (Zoladex).
    Walker KJ; Turkes AO; Turkes A; Zwink R; Beacock C; Buck AC; Peeling WB; Griffiths K
    J Endocrinol; 1984 Nov; 103(2):R1-4. PubMed ID: 6238116
    [TBL] [Abstract][Full Text] [Related]  

  • 27. A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients.
    Klioze SS; Miller MF; Spiro TP
    Am J Clin Oncol; 1988; 11 Suppl 2():S176-82. PubMed ID: 3149455
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Final height in sexually precocious girls after therapy with an intranasal analogue of gonadotrophin-releasing hormone (buserelin).
    Stasiowska B; Vannelli S; Benso L
    Horm Res; 1994; 42(3):81-5. PubMed ID: 7995616
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A review of the Hammersmith Hospital, St. Bartholomew's Hospital, and Institute of Urology studies of buserelin in advanced prostatic cancer.
    Waxman J
    Am J Clin Oncol; 1988; 11 Suppl 1():S16-8. PubMed ID: 3133943
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An LH-RH analogue (Zoladex) in the management of carcinoma of the prostate: a preliminary report comparing daily subcutaneous injections with monthly depot injections.
    Robinson MR; Denis L; Mahler C; Walker K; Stitch R; Lunglmayr G
    Eur J Surg Oncol; 1985 Jun; 11(2):159-65. PubMed ID: 3159598
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Response of circulating gonadotropin levels to GnRH agonist treatment in prostatic cancer.
    Huhtaniemi I; Venho P; Jacobi G; Rannikko S
    J Androl; 1991; 12(1):46-53. PubMed ID: 1901309
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Inhibition of serum androgen levels by chronic intranasal and subcutaneous administration of a potent luteinizing hormone-releasing hormone (LH-RH) agonist in adult men.
    Faure N; Labrie F; Lemay A; Bélanger A; Gourdeau Y; Laroche B; Robert G
    Fertil Steril; 1982 Mar; 37(3):416-24. PubMed ID: 6800852
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The treatment of postmenopausal women with advanced breast cancer with buserelin.
    Waxman JH; Harland SJ; Coombes RC; Wrigley PF; Malpas JS; Powles T; Lister TA
    Cancer Chemother Pharmacol; 1985; 15(2):171-3. PubMed ID: 3926333
    [TBL] [Abstract][Full Text] [Related]  

  • 34. A pharmacological evaluation of a new 3-month depot preparation of buserelin for prostatic cancer.
    Waxman J; Sandow J; Thomas H; James N; Williams G
    Cancer Chemother Pharmacol; 1989; 25(3):219-20. PubMed ID: 2513141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The clinical and endocrine assessment of three different antiandrogen regimens combined with a very long-acting gonadotrophin-releasing hormone analogue.
    Waxman J; Williams G; Sandow J; Hewitt G; Abel P; Farah N; Fleming J; Cox J; O'Donoghue EP; Sikora K
    Am J Clin Oncol; 1988; 11 Suppl 2():S152-5. PubMed ID: 2853934
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Buserelin as primary therapy in advanced prostatic carcinoma.
    Presant CA; Soloway MS; Klioze SS; Kosola JW; Yakabow AL; Mendez RG; Kennedy PS; Wyres MR; Naessig VL; Ford KS
    Cancer; 1985 Nov; 56(10):2416-9. PubMed ID: 3930064
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Pharmacokinetics and endocrine effects of the LHR analogue buserelin after subcutaneous implantation of a slow release preparation in prostatic cancer patients.
    Blom JH; Hirdes WH; Schröder FH; de Jong FH; Kwekkeboom DJ; van't Veen AJ; Sandow J; Krauss B
    Urol Res; 1989; 17(1):43-6. PubMed ID: 2493705
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Chemical castration using a depot LHRH-agonist as a palliative therapy concept in prostatic carcinoma--clinical, endocrinological and experimental studies].
    Kuber W; Treu T; Kratzik C; Girsch E; Zeillinger R; Spona J
    Wien Klin Wochenschr; 1990 Nov; 102(21):640-7. PubMed ID: 2148044
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Suppression of testicular steroidogenesis by the GnRH agonistic analogue Buserelin (HOE-766) in patients with prostatic cancer: studies in relation to dose and route of administration.
    Tolis G; Faure N; Koutsilieris M; Lemay A; Klioze S; Yakabow A; Fazekas AT
    J Steroid Biochem; 1983 Jul; 19(1C):995-8. PubMed ID: 6411994
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Buserelin in the treatment of prostatic cancer.
    Roila F
    Biomed Pharmacother; 1989; 43(4):279-85. PubMed ID: 2506941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.